Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference

Gene Ther. 2005 Jan;12(1):95-100. doi: 10.1038/sj.gt.3302391.

Abstract

Increase of Skp-2, which is involved in the degradation of cell cycle regulators including p27Kip1, p21 and c-myc, is one of the important mechanisms for dysregulation of cell cycles in various cancers. We applied RNA interference (RNAi) for Skp-2 by using HIV-lentiviral or adenoviral vectors for a human small-cell lung carcinoma cell line with increased Skp-2 to evaluate RNAi strategy for cancer gene therapy. HIV-lentivirus-mediated RNAi for Skp-2 resulted in efficient inhibition of the in vitro cell growth of cancer cells with increased Skp-2 through the increase of p27Kip1 and p21, but no significant effect on the growth of cells without high Skp-2 expression. Furthermore, intratumoral administration of adenovirus siRNA vector for Skp-2 efficiently inhibited growth of established subcutaneous tumor on NOD/SCID mice. These results indicate that the Skp-2 RNAi may be a useful strategy for gene therapy of cancers with high Skp-2 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Carcinoma, Small Cell / therapy*
  • Cell Line, Tumor
  • Genetic Engineering
  • Genetic Therapy / methods*
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • HIV / genetics
  • Lung Neoplasms / therapy*
  • Male
  • Mice
  • Mice, SCID
  • RNA Interference*
  • S-Phase Kinase-Associated Proteins / genetics*

Substances

  • S-Phase Kinase-Associated Proteins